Form 4: Director Behbahani Acquires BDTX Stock via Equity Compensation

Black Diamond Therapeutics director Ali Behbahani acquired 5,208 shares of common stock as part of his compensation plan, electing equity over cash.

Summary

• Director Ali Behbahani acquired 5,208 shares of Black Diamond Therapeutics, Inc. common stock on December 12, 2025.
• The shares were acquired at a price of $2.76 per share, based on the closing market price on December 11, 2025.
• This acquisition was in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, where the director elected to receive shares in lieu of cash compensation for annual services.
• Following this transaction, Ali Behbahani directly beneficially owns 86,649 shares.
• Additionally, Ali Behbahani indirectly beneficially owns 4,448,757 shares through New Enterprise Associates 16, L.P. (NEA 16), where he is a manager of the general partner, though he disclaims beneficial ownership for portions where he has no pecuniary interest.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director in lieu of cash compensation is generally viewed as a positive signal of confidence in the company's future, though it's a routine compensation event rather than a significant investment decision.

Positives

• A director electing to receive equity instead of cash compensation can signal confidence in the company's future performance and long-term value.
• The acquisition increases the director's direct stake in the company, further aligning their interests with those of shareholders.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports a compensation-related equity acquisition.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing reports a routine insider transaction related to director compensation. It does not provide broader industry context or trends, but the election of equity over cash compensation by a director is a common practice in the biotechnology sector, often seen as a sign of alignment with shareholder interests.

Comparison to Industry Standards

• This filing details a director's election to receive equity compensation in lieu of cash, a common practice across various industries, particularly in growth-oriented sectors like biotechnology.
• While no specific comparable companies or projects are mentioned, such compensation structures are standard for non-employee directors, aiming to align their interests with long-term shareholder value.
• The specific share price and volume are unique to Black Diamond Therapeutics and its compensation policy.

Management Changes

Corporate Governance

Legal Proceedings

• The filing does not mention any litigation or regulatory matters.

Related Party Transactions

• The reporting person's indirect beneficial ownership of 4,448,757 shares is through New Enterprise Associates 16, L.P. (NEA 16), where the reporting person is a manager of the general partner. This represents a significant indirect holding by an entity affiliated with the director.

Stakeholder Impact

• Shareholders: The director's election to receive equity compensation may be viewed positively, signaling alignment of interests and confidence in the company's long-term value.
• Employees/Customers/Suppliers/Creditors: No direct impact is indicated by this specific filing.

Next Steps

• The filing does not mention any specific future actions, events, or milestones.

Key Dates

Recommendation

While the director's decision to take equity compensation is a positive signal of confidence, this Form 4 filing alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. It's a routine disclosure of a compensation-related transaction. Investors should consider broader financial performance, strategic developments, and market conditions before making investment decisions. The 'hold' recommendation reflects the neutral but slightly positive nature of this specific piece of information within a larger investment thesis.

Keywords

Black Diamond Therapeutics, BDTX, Form 4, Insider Trading, Director Compensation, Equity Compensation, Stock Acquisition, Ali Behbahani, SEC Filing